Chemotherapy-induced Neutropenia Therapeutics Market Size, Share, Trends, Growth Outlook | 2025-2034

The Global Chemotherapy-induced Neutropenia Therapeutics Market Size is estimated at $656.1 Million in 2025 and is forecast to register an annual growth rate (CAGR) of 3.8% to reach $917.8 Million by 2034.

The global Chemotherapy-induced Neutropenia Therapeutics Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type (Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others).

An Introduction to Chemotherapy-induced Neutropenia Therapeutics Market in 2025

The Chemotherapy-induced Neutropenia Therapeutics Market comprises pharmaceuticals and biologics developed to prevent and manage neutropenia, a common side effect of chemotherapy characterized by low white blood cell counts. These therapeutics include granulocyte colony-stimulating factors (G-CSFs), biosimilars, and myeloid growth factors, supporting immune system recovery and reducing infection risks in cancer patients undergoing chemotherapy. In 2025, this market highlights biosimilar launches, long-acting G-CSFs, onco-supportive care protocols, and healthcare provider collaborations, ensuring optimal neutropenia management and treatment outcomes.

Chemotherapy-induced Neutropenia Therapeutics Market Competitive Landscape

The global Chemotherapy-induced Neutropenia Therapeutics Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Chemotherapy-induced Neutropenia Therapeutics Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Chemotherapy-induced Neutropenia Therapeutics Industry include- AbbVie Inc, Aurobindo Pharma, BeyondSpring Pharmaceuticals Inc, Coherus BioSciences, G1 Therapeutics Inc, GlaxoSmithKline PLC, Lupin, Merck & Co. Inc, Novartis AG, Spectrum Pharmaceuticals, Teva Pharmaceuticals Industries Ltd.

Chemotherapy induced Neutropenia Therapeutics Market Trend: Rise in Targeted Therapies

A notable trend in the Chemotherapy-induced Neutropenia (CIN) Therapeutics market is the increasing adoption of targeted therapies designed to mitigate neutropenic complications associated with chemotherapy. Pharmaceutical companies are focusing on developing innovative biologic agents and small molecule inhibitors that selectively target key pathways involved in neutrophil production and function. These targeted therapies offer the potential for more precise and effective management of CIN while minimizing adverse effects on other immune cell populations, reflecting a shift towards personalized and tailored approaches in supportive cancer care.

Chemotherapy induced Neutropenia Therapeutics Market Driver: Growing Incidence of Chemotherapy-induced Neutropenia

The primary driver for the Chemotherapy-induced Neutropenia (CIN) Therapeutics market is the rising incidence of neutropenic events among cancer patients undergoing chemotherapy. Neutropenia, characterized by abnormally low levels of neutrophils, increases the risk of serious infections and sepsis, leading to treatment interruptions, hospitalizations, and potentially life-threatening complications. With the expanding use of intensive chemotherapy regimens and the growing prevalence of aggressive malignancies, the incidence of CIN is expected to escalate, driving the demand for effective prophylactic and therapeutic interventions to prevent and manage neutropenic episodes, thereby sustaining market growth.

Chemotherapy induced Neutropenia Therapeutics Market Opportunity: Development of Novel Hematopoietic Growth Factors

An opportunity for market expansion in the Chemotherapy-induced Neutropenia (CIN) Therapeutics segment lies in the development of novel hematopoietic growth factors with improved efficacy, safety, and convenience profiles. While granulocyte colony-stimulating factors (G-CSFs) have been the cornerstone of CIN management, there is a need for next-generation agents that offer extended duration of action, reduced immunogenicity, and convenient dosing schedules to enhance patient compliance and treatment outcomes. Pharmaceutical companies can capitalize on this opportunity by investing in the research and development of long-acting G-CSFs, biosimilars, and novel agents targeting alternative pathways involved in neutrophil regulation, such as CXCR2 inhibitors and neutrophil elastase inhibitors. By addressing unmet needs in CIN therapy and offering innovative treatment options, companies can capture a larger share of the growing market and improve patient care in oncology supportive management.

Market Share Analysis: Granulocyte Colony-Stimulating Factor (G-CSF) Therapy is the fastest growing segment in the Chemotherapy induced Neutropenia Therapeutics industry

Among chemotherapy-induced neutropenia therapeutics, G-CSF therapy is experiencing rapid growth. G-CSF therapy involves the administration of synthetic versions of granulocyte colony-stimulating factor, a naturally occurring protein that stimulates the production of white blood cells, particularly neutrophils, in the bone marrow. Neutropenia, characterized by abnormally low levels of neutrophils, is a common side effect of chemotherapy and increases the risk of infections in cancer patients. G-CSF therapy helps mitigate this risk by stimulating the production and mobilization of neutrophils, thereby reducing the duration and severity of neutropenia and its associated complications. The growing recognition of the importance of maintaining optimal neutrophil counts during chemotherapy, coupled with the increasing incidence of chemotherapy-induced neutropenia, is driving the demand for G-CSF therapy. Hospital pharmacies and retail pharmacies are witnessing a surge in the distribution of G-CSF products, reflecting the growing utilization of this therapy in cancer care. As healthcare providers prioritize strategies to minimize the impact of neutropenia on patient outcomes and quality of life, G-CSF therapy is expected to continue its rapid growth trajectory, offering significant benefits to cancer patients undergoing chemotherapy.

Chemotherapy-induced Neutropenia Therapeutics Market Segmentation

By Type
Antibiotic Therapy
Granulocyte Colony-Stimulating Factor Therapy
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Chemotherapy-induced Neutropenia Therapeutics Companies

AbbVie Inc
Aurobindo Pharma
BeyondSpring Pharmaceuticals Inc
Coherus BioSciences
G1 Therapeutics Inc
GlaxoSmithKline PLC
Lupin
Merck & Co. Inc
Novartis AG
Spectrum Pharmaceuticals
Teva Pharmaceuticals Industries Ltd
* List not Exhaustive

Reasons to Buy the Chemotherapy-induced Neutropenia Therapeutics Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Chemotherapy-induced Neutropenia Therapeutics Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Chemotherapy-induced Neutropenia Therapeutics Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Chemotherapy-induced Neutropenia Therapeutics Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Chemotherapy-induced Neutropenia Therapeutics Market Size Outlook, $ Million, 2021 to 2030
3.2 Chemotherapy-induced Neutropenia Therapeutics Market Outlook by Type, $ Million, 2021 to 2030
3.3 Chemotherapy-induced Neutropenia Therapeutics Market Outlook by Product, $ Million, 2021 to 2030
3.4 Chemotherapy-induced Neutropenia Therapeutics Market Outlook by Application, $ Million, 2021 to 2030
3.5 Chemotherapy-induced Neutropenia Therapeutics Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Chemotherapy-induced Neutropenia Therapeutics Industry
4.2 Key Market Trends in Chemotherapy-induced Neutropenia Therapeutics Industry
4.3 Potential Opportunities in Chemotherapy-induced Neutropenia Therapeutics Industry
4.4 Key Challenges in Chemotherapy-induced Neutropenia Therapeutics Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Chemotherapy-induced Neutropenia Therapeutics Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Chemotherapy-induced Neutropenia Therapeutics Market Outlook by Segments
7.1 Chemotherapy-induced Neutropenia Therapeutics Market Outlook by Segments, $ Million, 2021- 2030
By Type
Antibiotic Therapy
Granulocyte Colony-Stimulating Factor Therapy
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
8 North America Chemotherapy-induced Neutropenia Therapeutics Market Analysis and Outlook To 2030
8.1 Introduction to North America Chemotherapy-induced Neutropenia Therapeutics Markets in 2024
8.2 North America Chemotherapy-induced Neutropenia Therapeutics Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Chemotherapy-induced Neutropenia Therapeutics Market size Outlook by Segments, 2021-2030
By Type
Antibiotic Therapy
Granulocyte Colony-Stimulating Factor Therapy
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
9 Europe Chemotherapy-induced Neutropenia Therapeutics Market Analysis and Outlook To 2030
9.1 Introduction to Europe Chemotherapy-induced Neutropenia Therapeutics Markets in 2024
9.2 Europe Chemotherapy-induced Neutropenia Therapeutics Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Chemotherapy-induced Neutropenia Therapeutics Market Size Outlook by Segments, 2021-2030
By Type
Antibiotic Therapy
Granulocyte Colony-Stimulating Factor Therapy
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
10 Asia Pacific Chemotherapy-induced Neutropenia Therapeutics Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Chemotherapy-induced Neutropenia Therapeutics Markets in 2024
10.2 Asia Pacific Chemotherapy-induced Neutropenia Therapeutics Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Chemotherapy-induced Neutropenia Therapeutics Market size Outlook by Segments, 2021-2030
By Type
Antibiotic Therapy
Granulocyte Colony-Stimulating Factor Therapy
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
11 South America Chemotherapy-induced Neutropenia Therapeutics Market Analysis and Outlook To 2030
11.1 Introduction to South America Chemotherapy-induced Neutropenia Therapeutics Markets in 2024
11.2 South America Chemotherapy-induced Neutropenia Therapeutics Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Chemotherapy-induced Neutropenia Therapeutics Market size Outlook by Segments, 2021-2030
By Type
Antibiotic Therapy
Granulocyte Colony-Stimulating Factor Therapy
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
12 Middle East and Africa Chemotherapy-induced Neutropenia Therapeutics Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Chemotherapy-induced Neutropenia Therapeutics Markets in 2024
12.2 Middle East and Africa Chemotherapy-induced Neutropenia Therapeutics Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Chemotherapy-induced Neutropenia Therapeutics Market size Outlook by Segments, 2021-2030
By Type
Antibiotic Therapy
Granulocyte Colony-Stimulating Factor Therapy
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
AbbVie Inc
Aurobindo Pharma
BeyondSpring Pharmaceuticals Inc
Coherus BioSciences
G1 Therapeutics Inc
GlaxoSmithKline PLC
Lupin
Merck & Co. Inc
Novartis AG
Spectrum Pharmaceuticals
Teva Pharmaceuticals Industries Ltd
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Type
Antibiotic Therapy
Granulocyte Colony-Stimulating Factor Therapy
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Others